Back

Vericiguat and cardiovascular outcomes in heart failure revisited: a bayesian reanalysis of 12,877 patients

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: New analyses and usage of old drugs Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Pedro Batista

(Brazil)

5 More presentations in this session

Presentation thumbnail
Effect of empagliflozin on adenosine triphosphate levels in vivo in patients with type 2 diabetes mellitus combined with heart failure
Miss U. Omurzakova (Bishkek, KG)
Abstract
Presentation thumbnail
Ambulatory milrinone in advanced heart failure: a single-center comparison of continuous and intermittent infusion strategies
Doctor A. Rioux (Quebec, CA)
Abstract
Presentation thumbnail
Long‑acting efficacy of oral stabilized bivalent liposomal iron therapy on iron balance and quality of life in chronic heart failure: more than iron supplementation
Doctor E. Tagliamonte (Nocera Inferiore, IT)
Abstract
Presentation thumbnail
Effects of low-dose dapagliflozin on heart failure–related outcomes in patients with heart failure and type 2 diabetes: a subanalysis of the dapper study
Doctor S. Ito (Osaka, JP)
Abstract
Presentation thumbnail
Short‑ and long‑term efficacy of oral stabilized bivalent liposomal iron versus intravenous ferric carboxymaltose in chronic heart failure patients: is there a difference?
Professor E. Tagliamonte (Nocera Inferiore, IT)
Abstract

Access the full session

Session thumbnail
New analyses and usage of old drugs

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Using bayesian method and network meta-analysis to augment the trial interpretation of RAAS inhibitor effects in patients
21 May 2023
thumbnail
Congress Presentation
Vericiguat clinical pharmacology programme: biopharmaceutical properties and potential intrinsic and extrinsic factor effects
28 August 2020
thumbnail
Congress Presentation
A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF)
10 May 2026
thumbnail
Congress Presentation
Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial
30 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources